[
  {
    "ts": null,
    "headline": "Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves",
    "summary": "Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how recent price moves and mixed growth metrics might fit into a broader long term thesis. See our latest analysis for Bristol-Myers Squibb. The recent 1 day share price return of 4.23% builds on short term momentum, with a 30 day share price return of 9.77% and a 90 day gain of 26.95%, while the 3 year total shareholder return of 9.60% decline shows that longer term holders...",
    "url": "https://finnhub.io/api/news?id=8dbfd20c49c88a30b5c81d764320eb0a61533b1461e979d8ccd25c75d741512d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767827421,
      "headline": "Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves",
      "id": 138033433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how recent price moves and mixed growth metrics might fit into a broader long term thesis. See our latest analysis for Bristol-Myers Squibb. The recent 1 day share price return of 4.23% builds on short term momentum, with a 30 day share price return of 9.77% and a 90 day gain of 26.95%, while the 3 year total shareholder return of 9.60% decline shows that longer term holders...",
      "url": "https://finnhub.io/api/news?id=8dbfd20c49c88a30b5c81d764320eb0a61533b1461e979d8ccd25c75d741512d"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks",
    "summary": "If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks through the key numbers that matter for value focused investors. The share price recently closed at US$54.42, with returns of 0.4% over 7 days, 4.4% over 30 days, 1.8% year to date, 0.1% over 1 year, negative 12.9% over 3 years and 1.4% over 5 years. Taken together, these figures present a mixed picture for anyone thinking about long term value. Recent headlines around...",
    "url": "https://finnhub.io/api/news?id=4b10c5b1ee17442c170260badd3ca1dde506c0175a24829ac89ef2b144e778c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767824000,
      "headline": "Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks",
      "id": 138033434,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks through the key numbers that matter for value focused investors. The share price recently closed at US$54.42, with returns of 0.4% over 7 days, 4.4% over 30 days, 1.8% year to date, 0.1% over 1 year, negative 12.9% over 3 years and 1.4% over 5 years. Taken together, these figures present a mixed picture for anyone thinking about long term value. Recent headlines around...",
      "url": "https://finnhub.io/api/news?id=4b10c5b1ee17442c170260badd3ca1dde506c0175a24829ac89ef2b144e778c3"
    }
  },
  {
    "ts": null,
    "headline": "3 Drug Stocks to Buy at a Discount",
    "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
    "url": "https://finnhub.io/api/news?id=9fcdcc39ce0addd277b2951b739d1aac0fe758a8e69a9b299ea726657eeba350",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767820800,
      "headline": "3 Drug Stocks to Buy at a Discount",
      "id": 138033031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.",
      "url": "https://finnhub.io/api/news?id=9fcdcc39ce0addd277b2951b739d1aac0fe758a8e69a9b299ea726657eeba350"
    }
  },
  {
    "ts": null,
    "headline": "Should You Chase the Rally in Alumis Stock Today?",
    "summary": "Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.",
    "url": "https://finnhub.io/api/news?id=f52f15084633e6f237aa4a582f2f9d56fa92ca19d97c0378296092ad3d2c5315",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767803749,
      "headline": "Should You Chase the Rally in Alumis Stock Today?",
      "id": 138033059,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s how you should play ALMS shares in 2026.",
      "url": "https://finnhub.io/api/news?id=f52f15084633e6f237aa4a582f2f9d56fa92ca19d97c0378296092ad3d2c5315"
    }
  },
  {
    "ts": null,
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=7da7b1f1164aca8ba029e203833e716a8b55c306099413246bada9c2b68a1e85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767794404,
      "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
      "id": 138027098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=7da7b1f1164aca8ba029e203833e716a8b55c306099413246bada9c2b68a1e85"
    }
  },
  {
    "ts": null,
    "headline": "Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical",
    "summary": "Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said",
    "url": "https://finnhub.io/api/news?id=94713ea8919cda7ca829f2ba15181e451906c7560e6538d62ca312b654a5619d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767780000,
      "headline": "Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical",
      "id": 138025933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said",
      "url": "https://finnhub.io/api/news?id=94713ea8919cda7ca829f2ba15181e451906c7560e6538d62ca312b654a5619d"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma race to snap up biotech assets as $170 billion patent cliff looms",
    "summary": "Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the best assets.",
    "url": "https://finnhub.io/api/news?id=a0c504f9e512dfd1f9c4c0c403aa8efad6e2dd4ab308b1791cfebe567d1454ed",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767753071,
      "headline": "Big Pharma race to snap up biotech assets as $170 billion patent cliff looms",
      "id": 138028004,
      "image": "https://image.cnbcfm.com/api/v1/image/108248856-1767718931887-gettyimages-1417392226-_x3m1126.jpeg?v=1767718937&w=1920&h=1080",
      "related": "BMY",
      "source": "CNBC",
      "summary": "Companies are facing a situation where they need to fill their pipelines, but also navigate a competitive environment for the best assets.",
      "url": "https://finnhub.io/api/news?id=a0c504f9e512dfd1f9c4c0c403aa8efad6e2dd4ab308b1791cfebe567d1454ed"
    }
  }
]